Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia
NCT01048502 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100
Last updated 2016-02-19
Summary
The purpose of this study is to better understand the anti-inflammatory benefits of two prescription medicines that are currently used to help people with cholesterol problems.
Fish oil, from eating certain kinds of fish and from supplement pills, has been used to help control cholesterol and reduce inflammation (the body's response to injury or sickness). Lovaza® is the brand name for prescription strength fish oil pills. In this study, we will be looking at how Lovaza® works to help reduce inflammation in healthy volunteers.
Tricor® is the brand name for prescription fenofibrate pills. Fenofibrate is a prescription medicine that many doctors give to people with high triglyceride (fat in the blood) levels. In this study, we will be looking at how Tricor® works to help reduce inflammation in healthy volunteers.
Endotoxin or lipopolysaccharide (LPS) is a small part of bacteria (that is no longer living) that can cause many of the effects similar to bacterial infections in humans. However, it can be administered in very small amounts to produce a mild immune response much the same as a 'flu' like illness. Within 1 ½ -3 hours after giving LPS by vein, a response consisting of fever, chills, headache, nausea and vomiting and generalized aches and pains will occur which lasts up to 6-8 hours. In addition to the flu like symptoms, the response causes temporary changes in cholesterol, triglycerides and blood sugar. Different people respond differently to LPS. We are using LPS in this study to bring on a temporary inflammatory response in the body and to compare the responses of people who receive Lovaza® or Tricor® to the responses of people who receive a placebo (pill that does not contain medicine).
Conditions
Interventions
- DRUG
-
Fenofibrate (Tricor) tablets
One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks
- DRUG
-
Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks
- DRUG
-
Lovaza
900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH - collaborator INDUSTRY
- lead OTHER
Principal Investigators
-
Muredach P Reilly, MB, MSCE · University of Pennsylvania
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-01-31
- Primary Completion
- 2011-05-31
- Completion
- 2011-05-31
Countries
- United States
Study Locations
More Related Trials
-
Lovaza Mechanisms of Action
NCT01301794 ·Status: UNKNOWN ·Phase: PHASE4
-
Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery
NCT01046604 ·Status: UNKNOWN ·Phase: PHASE4
-
Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides
NCT00504309 ·Status: COMPLETED ·Phase: NA
-
OMEGA-Study: Effect of Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After Myocardial Infarction
NCT00251134 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia
NCT01180764 ·Status: WITHDRAWN ·Phase: PHASE4
-
The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes
NCT00360217 ·Status: COMPLETED ·Phase: NA
-
The Effects of Omega-3 Fatty Acids on Aspirin Resistance
NCT00771914 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers
NCT00805870 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation
NCT00552084 ·Status: COMPLETED ·Phase: PHASE4
-
Fatty Acid Antiarrhythmia Trial (FAAT)
NCT00004559 ·Status: COMPLETED ·Phase: PHASE3
-
Breast Cancer Risk Biomarkers in Premenopausal Women
NCT01252277 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Fish Oil on Post Ablation Arrhythmias
NCT00791089 ·Status: TERMINATED ·Phase: PHASE4
-
Bioavailability of EPA + DHA in a SMEDS Formulation
NCT03443076 ·Status: COMPLETED ·Phase: NA
-
Supplementation of Glutamine and Fish Oil Versus Placebo in Patients With Heart Failure
NCT01534663 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation
NCT01813110 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia
NCT02305355 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Omega-3 Fatty Acids on Markers of Inflammation
NCT01129050 ·Status: COMPLETED ·Phase: NA
-
Omega 3 Fatty Acid Efficiency for Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting
NCT01175330 ·Status: TERMINATED ·Phase: PHASE3
-
Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients
NCT00346697 ·Status: COMPLETED ·Phase: PHASE4
-
Metabolic Actions of Omega-3 Fatty Acids
NCT01896414 ·Status: COMPLETED ·Phase: NA
-
The Effects of Omega-3 Fatty Acids on Metabolic Syndrome
NCT00350194 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)
NCT04335032 ·Status: UNKNOWN ·Phase: PHASE3
-
Omega 3 Action on Cardiovascular Risk Factors in Patients Treated With Statins
NCT00976872 ·Status: COMPLETED ·Phase: NA
-
Multi_center Study to Evaluate the Effect of N-3 Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation
NCT01235130 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging
NCT00729430 ·Status: COMPLETED ·Phase: PHASE3